−6.33USD
−352.09 MUSD
26.82 MUSD
54.74 M
About Agios Pharmaceuticals, Inc.
Sector
CEO
Brian M. Goff
Headquarters
Cambridge
Website
Employees (FY)
383
Founded
2007
ISIN
US00847X1046
FIGI
BBG000QY4ZD0
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
AGIO w24 2021. Waiting for clear uptrend.Weekly
Company not so old.
Consolidation of price
Daily
If price holds level of 57 could be buy, but i suppose profit depends on how fast they will do resarch of anticancer in 2022-2024 years.
Long on AGIOIsland type Reversal pattern on Abnormal Volume
New 30bar Highs on 2period ROC
Climactic action and supple demand imbalance
Longer term Wolf wave pattern on Weeklys and Daily’s
$AGIO Agios shares jump- sells Cancer Portfolio for $1.8bil
Could be a runner today on the news that is has agreed to sell its cancer portfolio .
"Servier will pay $1.8 billion in cash upfront and $200 million in potential future milestone payments for vorasidenib as well as a small percentage of royalties for U.S. net sales of acute myeloid leukemia tre
Agios Pharmaceuticals, Inc. Spikes pre market Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generatio
$AGIO Agios Pharma Bullish Trade above the 200MA
Alert set for break above the 200MA.
A cross above mid channel would be very bullish setting up a
move to the top of channel.
RSi very strong bounce of Mid-point
Volume beginning to increase
Short term target $46- $48
Agios Announces FDA Orphan Drug Designation Granted to MitapivatAGIO: Agios Pharmaceuticals, Inc.
2020-11-12 16:30:16
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease
AGIO 8H: BEST Level to BUY/HOLD 90% gains(SL/TP)(STOCKS)Why get subbed to me on Tradingview?
-TOP author on TradingView
-15+ years experience in markets
-Professional chart break downs
-Supply/Demand Zones
-TD9 counts / combo review
-Key S/R levels
-No junk on my charts
-Frequent updates
-Covering FX/crypto/US stocks
-24/7 uptime so constant updates
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of AGIO is 29.43 USD — it has increased by 1.38% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Agios Pharmaceuticals, Inc. stocks are traded under the ticker AGIO.
Agios Pharmaceuticals, Inc. is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
AGIO stock is 3.00% volatile and has beta coefficient of 1.53. Check out the list of the most volatile stocks — is Agios Pharmaceuticals, Inc. there?
One year price forecast for Agios Pharmaceuticals, Inc. has a max estimate of 49.00 USD and a min estimate of 29.00 USD.
AGIO earnings for the last quarter are −1.64 USD whereas the estimation was −1.70 USD which accounts for 3.67% surprise. Estimated earnings for the next quarter are −1.65 USD. See more details about Agios Pharmaceuticals, Inc. earnings.
Agios Pharmaceuticals, Inc. revenue for the last quarter amounts to 7.40 M USD despite the estimated figure of 7.53 M USD. In the next quarter revenue is expected to reach 7.92 M USD.
Yes, you can track Agios Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
AGIO stock has fallen by 3.19% compared to the previous week, the month change is a 0.27% rise, over the last year Agios Pharmaceuticals, Inc. has showed a 32.27% increase.
AGIO net income for the last quarter is −95.94 M USD, while the quarter before that showed −91.32 M USD of net income which accounts for −5.05% change. Track more Agios Pharmaceuticals, Inc. financial stats to get the full picture.
Today Agios Pharmaceuticals, Inc. has the market capitalization of 1.65 B, it has decreased by 3.38% over the last week.
No, AGIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, AGIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Agios Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 383.00 employees. See our rating of the largest employees — is Agios Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Agios Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Agios Pharmaceuticals, Inc. stock shows the neutral signal. See more of Agios Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Agios Pharmaceuticals, Inc. future price: according to them, AGIO price has a max estimate of 49.00 USD and a min estimate of 29.00 USD. Read a more detailed Agios Pharmaceuticals, Inc. forecast: see what analysts think of Agios Pharmaceuticals, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Agios Pharmaceuticals, Inc. EBITDA is −379.60 M USD, and current EBITDA margin is −1.43 K%. See more stats in Agios Pharmaceuticals, Inc. financial statements.